EP Patent

EP3808740A1 — Oral dosage forms comprising 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use

Assigned to Tersera Therapeutics LLC · Expires 2021-04-21 · 5y expired

What this patent protects

Compounds of formula I are disclosed, as well as compositions comprising them and methods of their use to treat, prevent and/or manage diseases and disorders.

USPTO Abstract

Compounds of formula I are disclosed, as well as compositions comprising them and methods of their use to treat, prevent and/or manage diseases and disorders.

Drugs covered by this patent

Patent Metadata

Patent number
EP3808740A1
Jurisdiction
EP
Classification
—
Expires
2021-04-21
Drug substance claim
No
Drug product claim
No
Assignee
Tersera Therapeutics LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.